Verici Dx PLC (VRCI) — Investment Research Note

Executive summary

Verici Dx is an AIM-listed precision diagnostics micro-cap developing RNA-signature blood tests for kidney transplant patients, with lead product Tutivia™ (post-transplant acute rejection detection) commercially launched in 2023 and reimbursed by Medicare at $2,650/test since April 2025. The trajectory since IPO (2020) has been delay-after-delay on commercial validation and reimbursement, multiple deeply dilutive equity raises (Feb 2024, July 2025 at 0.5p, June 2026 at 0.35p), and a going-concern flag in the FY24 audit — though Q1 FY26 finally shows real commercial traction (392 tests, +32% QoQ, FY26 guidance $5.1m). The single most important point for valuation is that the latest £2.5m raise increases share count by ~46%, leaves only ~£3m cash runway to end-2026, and means the equity story remains a binary execution-vs-dilution call rather than a defensible valuation anchor.

Fair value estimate

Range: 0.30p – 0.55p per share (implied market cap range: ~£8.7m – £16.0m on the enlarged ~2.91bn share count post-Jun 2026 placing).

Methodology: forward EV/Sales multiple anchored to FY26 management guidance of $5.1m (~£3.9m) revenue.

• Bear (0.30p): 1.5× EV/Sales, reflecting guidance miss risk and one further dilution cycle
• Central (0.42p): 2.5× EV/Sales (£10m EV) + ~£3m net cash post-raise = ~£13m mcap
• Bull (0.55p): 3.5× EV/Sales on guidance delivery, no further dilution near-term

vs. current market cap £8.3m (pre-placing, at 0.38p × 2.21bn shares): the new share count post-admission (23 June 2026) will be ~2.91bn, so the placing-adjusted current mcap is ~£11m at 0.38p. Versus a 0.42p central fair value the implied upside is ~+10% at the current 0.38p price, but the post-dilution baseline matters more than the headline price quote.

Sector context

Confirmed: Health Care / Health Care (specifically diagnostic testing / molecular diagnostics). Quality profile is well below typical health care peers — pre-profit, going-concern history, repeatedly dilutive financings. The natural listed peer is CareDx (NASDAQ: CDNA) (transplant diagnostics, AlloSure dd-cfDNA test), with whom VRCI competes directly in the post-transplant rejection-monitoring market; CDNA is a ~10× larger US peer with established commercial reach but a similarly bumpy reimbursement journey. Other distant peers: Natera (organ transplant diagnostics segment, Prospera) and to a lesser extent Renalytix (KidneyIntelX, also Mount Sinai-derived, also AIM-listed and struggling).

Investment thesis (3 bullets)

1. Reimbursement de-risked + early commercial inflection. Medicare LCD secured April 2025 at $2,650/test (covers ~68% of US transplant patients), 17 State Medicaid approvals, and Q1 FY26 test volumes +32% QoQ to 392 tests across 29 ordering centres representing ~20% of annual US kidney transplants. FY26 revenue guidance of $5.1m is the first credibly underpinned revenue forecast in the company's history 2026-06-05 Placing announcement; 2026-04-16 Q1 trading update.

2. Validated platform with optionality from Thermo Fisher partnership. PTRA (Clarava) licensed exclusively to Thermo Fisher with $2.8m+ already received, further milestone-linked payments and ongoing royalties on tests sold — a genuine commercial validation by a Tier-1 strategic and a non-dilutive revenue stream 2024-05-30 FY23 results; 2025-06-30 FY24 results. Protega (long-term fibrosis test) data due H1 2026, completes end-to-end transplant testing portfolio.

3. Asymmetric valuation at micro-cap level. Post-placing EV is ~£8m on FY26 guidance of £3.9m revenue (2× forward sales) — cheap if the company hits guide and scales toward breakeven ($10-12m revenue); a peer like CareDx historically traded at 3-6× sales. Strategic value to a larger transplant-diagnostics consolidator is plausible [inferred from peer activity].

Key risks (3 bullets)

1. Repeated dilutive equity raises and going-concern history. Three placings in ~16 months (Feb 2024 at 9p, July 2025 at 0.5p, June 2026 at 0.35p) with the share count more than 7× since end-2023. The FY24 audit report contained an explicit material uncertainty about going concern; current raise funds only to end-2026, and the GM authority explicitly seeks "Headroom" for further equity issuance within 12 months 2025-06-30 final results; 2026-06-05 placing announcement.

2. Repeated guidance misses and execution drag. Tutivia recognized revenue of $3.0m for FY25 was "slightly behind market expectations" despite $3.2m in orders; Medicare LCD took ~12 months longer than originally implied; PTRA milestone payment delayed into 2025+ 2026-02-05 FY25 trading update; 2025-06-30 final results. Pattern of optimistic timelines has consistently slipped.

3. Competitive and reimbursement risk. CareDx (AlloSure dd-cfDNA) is the entrenched leader with deep sales coverage; CMS clarifications in 2024 limited reimbursement to "single biomarker test per patient encounter" which is currently favourable but vulnerable to policy change 2023-09-30 H1 2025 interim. Commercial payor reimbursement remains highly variable and "requires significant judgement" in revenue recognition 2025-09-30 H1 2025 interim.

Operating leverage

VRCI has the classic asset-light specialty lab leverage profile but is sub-scale. Cost base is dominated by fixed items: H1 2025 employee costs $2.1m, R&D $0.65m, and depreciation/amortisation $0.3m on a revenue base of $1.9m, with cost of sales on testing revenue of $352k on $1.16m testing revenue (gross margin ~70%). The CLIA lab in Franklin, TN has been built and certified, sales team is intentionally small (~2 reps + one director of clinical partnerships hired late-2025), and additional test throughput drops at the gross-margin level with minimal incremental fixed overhead until a step-change in sales coverage is needed 2025-09-30 H1 2025 interim. At current ~$2,650 Medicare reimbursement and assumed ~70% gross margin, every incremental 1,000 tests = ~$1.85m incremental gross profit. To bridge from current ~$3m revenue to operating breakeven likely requires ~$10-12m revenue (roughly 4,000–4,500 tests/year), at which point the business would inflect sharply. A 10-20% beat on the FY26 $5.1m guidance would add ~$0.4-0.7m to gross profit but probably not to operating profit, since management has indicated commercial team expansion will absorb upside.

Value-trap signals

• Serial dilution: share count up ~7× in 16 months; placing prices (35×.5p → 0.5p → 0.35p) showing each raise at a successively lower price.
• Going-concern audit qualification in FY24 accounts, partially mitigated by recent raise but not fully removed.
• Repeated guidance shortfalls since 2023 commercial launch (Tutivia revenue, Medicare LCD timing, PTRA second milestone all slipped).
• Pre-emptive request for additional issuance headroom at the June 2026 GM ("Company anticipates requiring further equity funding within 12 months") — i.e., another raise is already telegraphed.
• Related-party participation by Substantial Shareholder Harwood Capital and management in every placing — supportive but indicative of limited institutional demand.

Earnings vs. expectations

• FY23: $1.0m license revenue (Thermo Fisher milestone) — first revenue, met expectations as it was milestone-defined.
• FY24: $3.3m revenue, dominated by Thermo Fisher milestones ($3.0m); minimal Tutivia revenue due to delayed LCD — missed prior commercial expectations.
• H1 2025: $1.9m revenue ($1.16m Tutivia, $0.75m Thermo Fisher) — Tutivia ramp slower than implied at IPO.
• FY25: $3.0m Tutivia revenue vs ~$3.2m ordered, "slightly behind market expectations" per management; $3.8m total — modest miss.
• Q1 FY26: 392 tests "comfortably ahead of management expectations" — first credible beat.

Pattern: persistent misses 2022-2025, with first sign of operational beat only in Q1 2026. Management guidance has been chronically optimistic on timing.

Conviction

Conviction: 2 (low).

Anchors: (i) clean disclosure of test volumes, reimbursement rates, and cash position; (ii) Medicare LCD and Thermo Fisher partnership are tangible, verifiable de-risking events; (iii) post-placing cash position is clearly stated.

Caveats: (i) the fair value rests heavily on management's $5.1m FY26 guidance, and the company has missed every guidance set since 2023; (ii) commercial-payor revenue recognition involves "significant judgement and estimation"; (iii) further dilution explicitly telegraphed within 12 months, which structurally caps any near-term equity re-rating.